☆ 4.8 Article

Reducedhumoral response against variants of concern in childhood solid cancer patients compared to adult patients and healthy children after SARS-CoV-2 vaccination

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Subsequent malignant neoplasms in the childhood cancer survivor study: Occurrence of cancer types in which human papillomavirus is an established etiologic risk factor

Tara O. Henderson et al.

Summary: Childhood cancer survivors are at increased risk for subsequent malignant neoplasms in sites susceptible to HPV-associated malignancies. Further research examining the role of HPV in the etiology of SMN and promoting HPV vaccination and surveillance guidelines for SMNHPV in cancer survivors is needed.

CANCER (2022)

Add to Collection

Review Oncology

Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis

Atsushi Sakuraba et al.

Summary: Patients with cancer, especially those with hematologic B-cell malignancies, have a lower serologic response to COVID-19 vaccines. Additional strategies for prophylaxis should be considered for cancer patients.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Letter Medicine, General & Internal

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer

Annika Fendler et al.

LANCET (2022)

Add to Collection

Article Oncology

SARS-CoV-2 vaccine acceptability among caregivers of childhood cancer survivors

Courtney E. Wimberly et al.

Summary: The study aimed to investigate the willingness/hesitancy of caregivers of childhood cancer survivors (CCS) to vaccinate themselves and their children against COVID-19. Results showed that 21% of caregivers hesitated to vaccinate themselves and 29% hesitated to vaccinate their CCS, with concerns related to the speed of COVID-19 vaccine development and inadequate safety/efficacy data in children and CCS. The findings emphasize the importance of vaccination education and timely dissemination of relevant information among highly engaged families within the medical community.

PEDIATRIC BLOOD & CANCER (2022)

Add to Collection

Letter Oncology

COVID-19 vaccination for children with cancer

Rishi S. Kotecha

PEDIATRIC BLOOD & CANCER (2022)

Add to Collection

Article Oncology

Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study

Sheena Mukkada et al.

Summary: The study found that around one fifth of children and adolescents with cancer infected with SARS-CoV-2 developed severe or critical illness, with a higher death rate than in the general pediatric population. Factors associated with treatment modification were different from those associated with disease severity, highlighting the need to raise global awareness of the high risk of severe COVID-19 illness in children and adolescents with cancer. These findings could inform clinical guidelines and improve care practices for this vulnerable population.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

SARS-CoV-2 vaccines for cancer patients: a call to action

Chiara Corti et al.

Summary: The COVID-19 pandemic has affected over 96 million people globally, with cancer patients at a higher risk of severe illness. Efforts to develop effective vaccines are crucial, but cancer patients may be underrepresented in clinical trials. Real-time data on vaccine recipients, including cancer patients, is needed to ensure safety and efficacy. Prioritizing vaccinations for cancer patients and implementing pharmacovigilance registries are important steps in attenuating the consequences of the pandemic for this vulnerable population.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis

Yifei Ma et al.

Summary: This study investigated the impact of PD-1B on vaccination outcomes in patients receiving cancer treatment. Results showed that seroconversion was not affected in patients receiving PD-1B after COVID-19 vaccination. A nomogram predicting the risk of seroconversion failure was developed, with variables including age, pathology, and chemotherapy status.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Medicine, General & Internal

Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China

Xin Peng et al.

Summary: Cancer patients, particularly breast cancer survivors, face high risk of COVID-19 infection but have low vaccination rates. Factors contributing to vaccination hesitancy included current treatment, lack of information, and influence of healthcare providers. Effective communication, clear vaccination guidelines, and timely information dissemination could help combat vaccine hesitancy among this population.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Article Oncology

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Leticia Monin et al.

Summary: The study aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in cancer patients. The results showed poor efficacy of a single vaccine dose in cancer patients, with significantly increased immunogenicity in solid cancer patients after a vaccine boost at day 21. Therefore, it is recommended to prioritize cancer patients for an early second dose on day 21.

LANCET ONCOLOGY (2021)

Add to Collection

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Bihua Han et al.

Summary: The study evaluated the safety, tolerability, and immunogenicity of the candidate COVID-19 vaccine CoronaVac containing inactivated SARS-CoV-2 in children and adolescents aged 3-17 years. The research findings indicate that the 3.0 μg dose induced higher levels of neutralizing antibodies compared to the 1.5 μg dose, supporting the use of the 3.0 μg dose for further studies in this age group.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

Robert W. Frenck et al.

Summary: The BNT162b2 vaccine showed favorable safety profile and a greater immune response in 12-to-15-year-old recipients compared to young adults, and demonstrated high effectiveness against Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Oncology

Challenges posed by COVID-19 to children with cancer

Rishi S. Kotecha

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Vaccination in pediatric cancer survivors: Vaccination rates, immune status, and knowledge regarding compliance

Daniel K. Choi et al.

PEDIATRIC BLOOD & CANCER (2020)

Add to Collection

Article Medicine, General & Internal

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis

Jonathan A. C. Sterne et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Oncology

Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort

Todd M. Gibson et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Oncology

Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients

Te-Yu Hung et al.

CANCER (2017)

Add to Collection

Article Oncology

Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer

Rishi S. Kotecha et al.

CANCER MEDICINE (2016)

Add to Collection

Article Statistics & Probability

cem: Software for Coarsened Exact Matching

Stefano M. Iacus et al.

Journal of Statistical Software (2015)

Add to Collection

Review Medicine, General & Internal

Influenza vaccination in children being treated with chemotherapy for cancer

Ginette M. Goossen et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)

Add to Collection

Article Immunology

Safety and Immunogenicity of Live Attenuated and Inactivated Influenza Vaccines in Children With Cancer

Silvana Carr et al.

JOURNAL OF INFECTIOUS DISEASES (2011)

Add to Collection

Article Mathematical & Computational Biology

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

Peter C. Austin

STATISTICS IN MEDICINE (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.